Dirk Kersten, serving as a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), has executed a substantial divestment of company equity. According to a Form 4 filing submitted to the Securities and Exchange Commission, Kersten sold common stock valued at approximately $5.46 million. The transactions took place on June 22 and June 23, 2026, with execution prices ranging between $20.5703 and $21.4742 per share.
These sales were facilitated through a Rule 10b5-1 trading plan, which was established by ForDyne B.V. on November 11, 2025. On June 22, Kersten disposed of 190,676 shares at a weighted average price of $20.5703. Individual prices for this block ranged from $20.13 to $20.97. The following day, June 23, involved two distinct transactions. First, 71,629 shares were sold at a weighted average price of $21.0357, with prices falling between $20.45 and $21.44. Additionally, a smaller block of 1,657 shares was sold at a weighted average price of $21.4742, with individual prices ranging from $21.45 to $21.495.
The execution prices align closely with the stock's trading level of $20.35. This price point represents a 91% surge over the past year. The stock remains well above its 52-week low of $8.06 but continues to trade below its recent peak of $25. Kersten's holdings are indirect, maintained through ForDyne B.V. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. and Forbion Growth Opportunities Fund II Cooperatief U.A. Kersten serves as a partner of Forbion Management B.V. and Forbion Growth II Management B.V., and is a member of their respective investment committees. These entities hold voting and dispositive power over the shares, though Kersten disclaims beneficial ownership except for his pecuniary interest.
Following these transactions, Kersten's indirect holdings in Dyne Therapeutics common stock totaled 3,848,256 shares. Financial analysis indicates that Dyne holds more cash than debt on its balance sheet, with liquid assets exceeding short-term obligations. However, the company remains unprofitable, with analysts not anticipating profitability this year.
In regulatory developments, Dyne has submitted a Biologics License Application to the U.S. Food and Drug Administration for zeleciment rostudirsen, a treatment for Duchenne muscular dystrophy. The application seeks accelerated approval using dystrophin as a surrogate endpoint. The company has also completed enrollment in the expansion cohort of its Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1, with topline data expected in early 2027.
Financially, Dyne has amended its loan agreement with Hercules Capital, expanding its debt facility to $400 million. This includes two new $50 million tranches and an increase to the final tranche by $25 million. One new $50 million tranche has already been borrowed. Additionally, Barry Greene has been appointed to the board, bringing over 30 years of biopharmaceutical experience.